This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer (FLASH)

This study has been completed.
Information provided by (Responsible Party):
SillaJen, Inc. ( Jennerex Biotherapeutics ) Identifier:
First received: June 23, 2012
Last updated: January 19, 2016
Last verified: January 2016
This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in five weekly IV infusions.

Condition Intervention Phase
Hepatocellular Carinoma Biological: JX-594 recombinant vaccina GM-CSF Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC)

Resource links provided by NLM:

Further study details as provided by SillaJen, Inc. ( Jennerex Biotherapeutics ):

Primary Outcome Measures:
  • Tumor response [ Time Frame: CT scans evaluated at Weeks 6, 12, 18, 24, 30, 36, 42, 48 ]
    CT scans every six weeks until documented progression or date of death, whichever comes first, assessed up to 104 weeks.

Secondary Outcome Measures:
  • Safety profile of JX-594 [ Time Frame: Safety assessments related to JX-594 up to 28 days after last IV infusion ]
    Safety will be assessed by the number of adverse events (AEs) and serious adverse events (SAEs) up to 28 days after last JX-594 administration for an expected average of 52 weeks

  • Time to progression [ Time Frame: From the earliest date of either documented progression or death of any cause, assessed up to 104 weeks ]
  • Overall survival [ Time Frame: From date of final clinic visit until date of death, assessed up to 104 weeks ]
    After radiographic progression, beginning other cancer therapy, or early withdrawal, patients and/or their specified contacts will continue to be contacted approximately every 4 weeks for survival and information on subsequent anti-cancer therapy including dose, duration, significant associated toxicities and efficacy.

Enrollment: 16
Study Start Date: June 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: JX-594 recombinant vaccina GM-CSF
JX-594 recombinant vaccina GM-CSF
Biological: JX-594 recombinant vaccina GM-CSF
Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

KEY Inclusion Criteria:

  • Histologic or cytologic confirmation of advanced primary hepatocellular carcinoma (HCC)
  • Measurable tumor (at least one tumor with ≥1 cm LD of contrast-enhancement during the arterial phase on CT scanning)
  • ECOG performance status 0, 1 or 2
  • Child-Pugh Class A; or Child-Pugh Class B7 without clinically significant ascites
  • Platelet count ≥50,000 plts/mm3
  • WBC count ≥2,000 cells/mm3 and ≤50,000 cells/mm3
  • Hemoglobin ≥10 g/dL
  • Adequate liver function

KEY Exclusion Criteria:

  • Received sorafenib as previous treatment for HCC for more than 14 days
  • History of severe exfoliative skin condition (e.g., eczema or atopic dermatitis requiring systemic therapy for > 4 weeks)
  • Prior treatment with JX-594
  • Known significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication
  • Severe or unstable cardiac disease
  • Viable CNS malignancy associated with clinical symptoms
  • Pregnant or nursing an infant
  • Significant bleeding event within the last 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01636284

United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 85259
United States, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229
Korea, Republic of
Pusan National University Hospital
Pusan, Korea, Republic of
Pusan National University Yangsan Hospital
Yangsan, Korea, Republic of
University Clinic of Navarra
Navarra, Spain
Sponsors and Collaborators
Jennerex Biotherapeutics
Study Director: James Burke, MD Jennerex Biotherapeutics
  More Information

Responsible Party: Jennerex Biotherapeutics Identifier: NCT01636284     History of Changes
Other Study ID Numbers: JX594-IV-HEP021
Study First Received: June 23, 2012
Last Updated: January 19, 2016

Keywords provided by SillaJen, Inc. ( Jennerex Biotherapeutics ):
Liver Cancer
first line HCC

Additional relevant MeSH terms:
Poxviridae Infections
DNA Virus Infections
Virus Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 20, 2017